Benefits of and safety concerns associated with drug-eluting coronary stents

References

• Lagerqvist B, James SK, Stenestrand U et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med.356(10), 1009–1019 (2007).
   PubMed Web of Science ®Google Scholar
• Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J.27(23), 2784–2814 (2006).
   PubMed Web of Science ®Google Scholar
• Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation115(11), 1440–1455; discussion 1455 (2007).
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Daemen J. The scaar registry or the swedish yo-yo. Eurointervention3, 297–300 (2007).
   Google Scholar
• Serruys PW, Daemen J. Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation115(11), 1433–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol.52(14), 1134–1140 (2008).
   PubMed Web of Science ®Google Scholar
• Rao SV, Shaw RE, Brindis RG et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am. Heart J.152(2), 321–326 (2006).
   Google Scholar
• Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet311(8058), 263–263 (1978).
   Google Scholar
• Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med.316(12), 701–706 (1987).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N. Engl. J. Med.324(1), 13–17 (1991).
   PubMed Web of Science ®Google Scholar
• Barragan P, Sainsous J, Silvestri M et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet. Cardiovasc. Diagn.32(2), 133–138 (1994).
   PubMedGoogle Scholar
• Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med.334(17), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation98(16), 1597–1603 (1998).
   PubMed Web of Science ®Google Scholar
• Morice Mc, Zemour G, Benveniste E et al. Intracoronary stenting without coumadin: one month results of a french multicenter study. Cathet. Cardiovasc. Diagn.35(1), 1–7 (1995).
   PubMedGoogle Scholar
• Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation91(6), 1676–1688 (1995).
   PubMed Web of Science ®Google Scholar
• Costa Ma, Sabate M, Van Der Giessen WJ et al. Late coronary occlusion after intracoronary brachytherapy. Circulation100(8), 789–792 (1999).
   PubMed Web of Science ®Google Scholar
• Van Der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation94(7), 1690–1697 (1996).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation103(2), 192–195 (2001).
   PubMed Web of Science ®Google Scholar
• Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann. Intern. Med.148(3), 234–238 (2008).
   Google Scholar
• Mcfadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet364(9444), 1519–1521 (2004).
   PubMed Web of Science ®Google Scholar
• Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart86(3), 262–264 (2001).
   PubMed Web of Science ®Google Scholar
• Kerner A, Gruberg L, Kapeliovich M, Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc. Interv.60(4), 505–508 (2003).
   PubMed Web of Science ®Google Scholar
• Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-cypher registry. Circulation113(11), 1434–1441 (2006).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol.98(3), 352–356 (2006).
   PubMed Web of Science ®Google Scholar
• Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation113(8), 1108–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol.48(12), 2584–2591 (2006).
   PubMed Web of Science ®Google Scholar
• Maluenda G, Lemesle G, Waksman R. A critical appraisal of the safety and efficacy of drug-eluting stents. Clin. Pharmacol. Ther.85(5), 474–480 (2009).
   Google Scholar
• Serruys P. FDA Panel, 7 and 8 December 2006 – the impact on our practice and research. Eurointervention2, 405–407 (2007).
   Google Scholar
• Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med.356(10), 989–997 (2007).
   PubMed Web of Science ®Google Scholar
• James Sk, Stenestrand U, Lindback J et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in sweden. N. Engl. J. Med.360(19), 1933–1945 (2009).
   PubMed Web of Science ®Google Scholar
• Farb A, Boam AB. Stent thrombosis redux – the FDA perspective. N. Engl. J. Med.356(10), 984–987 (2007).
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet370(9591), 937–948 (2007).
   PubMed Web of Science ®Google Scholar
• Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med.356(10), 998–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med.356(10), 1030–1039 (2007).
   PubMed Web of Science ®Google Scholar
• Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA297(18), 2001–2009 (2007).
   PubMed Web of Science ®Google Scholar
• Ko DT, Chiu M, Guo H et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J. Am. Coll. Cardiol.53(19), 1773–1782 (2009).
   Google Scholar
• Marroquin OC, Selzer F, Mulukutla SR et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N. Engl. J. Med.358(4), 342–352 (2008).
   PubMedGoogle Scholar
• Lasala JM, Cox DA, Lewis SJ et al. Expanded use of the taxus express stent: two-year safety insights from the 7,500 patient arrive registry programme. EuroIntervention5(1), 67–77 (2009).
   Google Scholar
• Brodie Br, Stuckey T, Downey W et al. Outcomes and complications with off-label use of drug-eluting stents: results from the stent (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc. Interv.1(4), 405–414 (2008).
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation119(25), 3198–3206 (2009).
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation115(17), 2344–2351 (2007).
   PubMed Web of Science ®Google Scholar
• De La Torre-Hernandez JM, Alfonso F, Hernandez F et al. Drug-eluting stent thrombosis: results from the multicenter spanish registry ESTROFA (estudio espanol sobre trombosis de stents farmacoactivos). J. Am. Coll. Cardiol.51(10), 986–990 (2008).
   PubMed Web of Science ®Google Scholar
• Garg S, Bourantas C, Thackray S, Alamgir F. Echocardiographic identification of ventricular septal rupture caused by acute stent thrombosis. J. Clin. Ultrasound (2009) (Epub ahead of print).
   Google Scholar
• Lasala JM, Cox DA, Dobies D et al. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the taxus arrive registries. Circ. Cardiovasc. Intervent.2(4), 285–293 (2009).
   Google Scholar
• Mauri L, Hsieh WH, Massaro JM, Ho KK, D’agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med.356(10), 1020–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am. J. Cardiol.95(12), 1469–1472 (2005).
   Google Scholar
• Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J. Am. Coll. Cardiol.45(6), 941–946 (2005).
   PubMed Web of Science ®Google Scholar
• Moreno R, Fernandez C, Hernandez R et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J. Am. Coll. Cardiol.45(6), 954–959 (2005).
   PubMed Web of Science ®Google Scholar
• Roukoz H, Bavry AA, Sarkees ML et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am. J. Med.122(6), 581.e1–10 (2009).
   Google Scholar
• Weisz G, Leon MB, Holmes DR Jr et al. Five-year follow-up after sirolimus-eluting stent implantation results of the sirius (sirolimus-eluting stent in de-novo native coronary lesions) trial. J. Am. Coll. Cardiol.53(17), 1488–1497 (2009).
   PubMed Web of Science ®Google Scholar
• Onuma Y. Incidence of late stent thrombosis up to 5 years after implantation of drug eluting stents in clinical practice. Presentated at: The European Society of Cardiology Meeting. Barcelona, Spain, 31 August 2009.
   Google Scholar
• Pinto Slottow TL, Steinberg DH, Roy PK et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am. J. Cardiol.102(3), 298–303 (2008).
   PubMed Web of Science ®Google Scholar
• James S. Long-term outcome with drug-eluting stents vs bare-metal stents in sweden: one additional year of follow-up. Presentated at: The European Society of Cardiology Meeting. Vienna, Austria, 1–5 September 2007.
   Google Scholar
• Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol.52(5), 333–342 (2008).
   PubMed Web of Science ®Google Scholar
• Guagliumi G, Sirbu V, Suzuki N et al. A prospective randomised controlled study using optical coherence tomography to evaluate strut coverage of sirolimus-, paclitaxel, and zotarolimus-eluting coronary stents in long lesions requiring overlapping (ODESSA-oct for des safety) [abstract]. Am. J. Cardiol.102(Suppl.1), 8 (2008).
   Google Scholar
• Kim J-S, Jang I-K, Kim J-S et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9 month follow up: comparison with sirolimus-eluting stents. Heart95(23), 1907–1912 (2009).
   PubMed Web of Science ®Google Scholar
• Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur. Heart J.31(2), 165–176 (2010).
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Virmani R, Liistro F, Stankovic G et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation106(21), 2649–2651 (2002).
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation109(6), 701–705 (2004).
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the research on adverse drug events and reports (radar) project. J. Am. Coll. Cardiol.47(1), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention4(Suppl. C), C7–C10 (2008).
   Google Scholar
• Park SJ. Comparison of sirolimus- and paclitaxel-eluting stents vs zotarolimus-eluting stents in real world practice: the zest randomized controlled trial. Presented at: I2 summit at The American College of Cardiology Scientific Sessions. Orlando, FL, USA, 29–31 March 2009.
   Google Scholar
• Garg S, Serruys PW, Onuma Y et al. Three year clinical follow up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. The SPIRIT II trial. J. Am. Coll. Cardiol. Intv.2(12), 1190–1198 (2009).
   Google Scholar
• Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation119(5), 680–686 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Callahan KP, Malinin AI, Serebruany Vl, Gillis J. Could stent design affect platelet activation? Results of the Platelet Activation in Stenting (PAST) study. J. Invasive Cardiol.14(10), 584–589 (2002).
   PubMedGoogle Scholar
• Hehrlein C, Zimmermann M, Metz J, Ensinger W, Kubler W. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron. Artery Dis.6(7), 581–586 (1995).
   PubMed Web of Science ®Google Scholar
• De Scheerder I, Sohier J, Wang K et al. Metallic surface treatment using electrochemical polishing decreases thrombogenicity and neointimal hyperplasia after coronary stent implantation in a porcine model (abstract). Eur. Heart J.18(Suppl.), 153 (1997).
   Google Scholar
• Van Der Hoeven BL, Liem SS, Dijkstra J et al. Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the mission. Intervention study. JACC Cardiovasc. Interv.1(2), 192–201 (2008).
   PubMed Web of Science ®Google Scholar
• De Jaegere P, Mudra H, Figulla H et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the multicenter ultrasound stenting in coronaries study (music study). Eur. Heart J.19(8), 1214–1223 (1998).
   PubMed Web of Science ®Google Scholar
• Van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the dutch stent thrombosis registry. J. Am. Coll. Cardiol.53(16), 1399–1409 (2009).
   PubMed Web of Science ®Google Scholar
• Fujii K, Carlier SG, Mintz GS et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J. Am. Coll. Cardiol.45(7), 995–998 (2005).
   PubMed Web of Science ®Google Scholar
• Alfonso F, Suarez A, Perez-Vizcayno MJ et al. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J. Am. Coll. Cardiol.50(21), 2095–2097 (2007).
   Google Scholar
• Liu X, Doi H, Maehara A et al. A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC Cardiovasc. Interv.2(5), 428–434 (2009).
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Koga H, Serikawa T et al. Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion. Catheter Cardiovasc. Interv.73(2), 205–211 (2009).
   PubMed Web of Science ®Google Scholar
• Mintz GS. What to do about late incomplete stent apposition? Circulation115(18), 2379–2381 (2007).
   Google Scholar
• Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation115(18), 2426–2434 (2007).
   PubMed Web of Science ®Google Scholar
• Hassan AK, Bergheanu SC, Stijnen T et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur. Heart J. (2009) (Epub ahead of print).
   Google Scholar
• Kubo T, Imanishi T, Kitabata H et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study. JACC Cardiovasc. Imaging1(4), 475–484 (2008).
   PubMed Web of Science ®Google Scholar
• Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation120(5), 391–399 (2009).
   PubMed Web of Science ®Google Scholar
• Waksman R. Late thrombosis after radiation. Sitting on a time bomb. Circulation100(8), 780–782 (1999).
   PubMedGoogle Scholar
• Tanabe K, Serruys PW, Degertekin M et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation111(7), 900–905 (2005).
   PubMed Web of Science ®Google Scholar
• Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes. Circ. Cardiovasc. Intervent.2(1), 35–42 (2009).
   Google Scholar
• Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med.360(10), 961–972 (2009).
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Colombo A, Lefevre T et al. The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study Part II (ARTS II). Eur. Heart J.28(4), 433–442 (2007).
   PubMed Web of Science ®Google Scholar
• Ferenc M, Gick M, Kienzle RP et al. Randomized trial on routine vs provisional T-stenting in the treatment of de novo coronary bifurcation lesions. Eur. Heart J.29(23), 2859–2867 (2008).
   PubMed Web of Science ®Google Scholar
• Colombo A, Bramucci E, Sacca S et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (coronary bifurcations: application of the Crushing Technique Using Sirolimus-Eluting Stents) study. Circulation119(1), 71–78 (2009).
   PubMed Web of Science ®Google Scholar
• Erglis A, Kumsars I, Niemela M et al. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic Stent Technique study. Circ. Cardiovasc. Intervent.2(1), 27–34 (2009).
   PubMed Web of Science ®Google Scholar
• Valenti R, Migliorini A, Signorini U et al. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur. Heart J.29(19), 2336–2342 (2008).
   PubMed Web of Science ®Google Scholar
• Shen ZJ, Garcia-Garcia HM, Garg S et al. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital – (RESEARCH) registry. Catheter Cardiovasc. Interv.74(7), 979–986 (2009).
   Google Scholar
• Fox KA, Poole-Wilson P, Clayton TC et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: The British Heart Foundation Rita 3 randomised trial. Lancet366(9489), 914–920 (2005).
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet361(9351), 13–20 (2003).
   PubMed Web of Science ®Google Scholar
• Ong AT, Hoye A, Aoki J et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J. Am. Coll. Cardiol.45(6), 947–953 (2005).
   PubMed Web of Science ®Google Scholar
• Tolleson TR, Newby LK, Harrington RA et al. Frequency of stent thrombosis after acute coronary syndromes (from the Symphony and 2nd Symphony trials). Am. J. Cardiol.92(3), 330–333 (2003).
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Kolodgie F, Virmani R. Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety? Eur. Heart J.30(15), 1828–1830 (2009).
   Google Scholar
• Spertus Ja, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the premier registry. Circulation113(24), 2803–2809 (2006).
   PubMed Web of Science ®Google Scholar
• Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, Van Domburg R, Serruys PW. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc. Interv.2(6), 534–541 (2009).
   PubMed Web of Science ®Google Scholar
• Stone GW, Lansky AJ, Pocock SJ et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N. Engl. J. Med.360(19), 1946–1959 (2009).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Dibra A, Spaulding C et al. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur. Heart J.28(22), 2706–2713 (2007).
   PubMed Web of Science ®Google Scholar
• Brar SS, Leon MB, Stone GW et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J. Am. Coll. Cardiol.53(18), 1677–1689 (2009).
   PubMedGoogle Scholar
• Spaulding C, Henry P, Teiger E et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N. Engl. J. Med.355(11), 1093–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Cola C, Brugaletta S, Martin Yuste V, Campos B, Angiolillo DJ, Sabate M. Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc. Health Risk Manag.5(1), 101–119 (2009).
   PubMedGoogle Scholar
• Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the evastent matched-cohort registry. J. Am. Coll. Cardiol.50(6), 501–508 (2007).
   PubMed Web of Science ®Google Scholar
• Lincoff AM. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation107(11), 1556–1559 (2003).
   PubMedGoogle Scholar
• Niles NW, Mcgrath PD, Malenka D et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease study group. J. Am. Coll. Cardiol.37(4), 1008–1015 (2001).
   PubMed Web of Science ®Google Scholar
• West NE, Ruygrok PN, Disco CM et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation109(7), 867–873 (2004).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Antiplatelet therapy in Type 2 diabetes mellitus. Curr. Opin. Endocrinol. Diabetes Obes.14(2), 124–131 (2007).
   PubMedGoogle Scholar
• Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N. Engl. J. Med.339(23), 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-Cure study. Lancet358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation116(7), 745–754 (2007).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation115(11), 1433–1439; discussion 1439 (2007).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the ravel trial. J. Am. Coll. Cardiol.50(14), 1299–1304 (2007).
   PubMed Web of Science ®Google Scholar
• Grube E, Silber S, Hauptmann KE et al. Taxus I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation107(1), 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Grines CL, Bonow RO, Casey DE Jr et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with Representation from the American College of Physicians. Circulation115(6), 813–818 (2007).
   PubMed Web of Science ®Google Scholar
• Chhatriwalla AK, Bhatt DL. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely. Circ. Cardiovasc. Intervent.1(3), 217–225 (2008).
   Google Scholar
• Colombo A, Gerber RT. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely. Circ. Cardiovasc. Intervent.1(3), 226–232 (2008).
   Google Scholar
• Schulz S, Schuster T, Mehilli J et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4 year period. Eur. Heart J.30(22), 2714–2721 (2009).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation107(7), 966–972 (2003).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes55(3), 780–784 (2006).
   PubMed Web of Science ®Google Scholar
• Wykrzykowska JJ, Warnholtz A, de Jaeger P et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J. Thromb. Thrombolysis28(4), 410–417 (2009).
   PubMed Web of Science ®Google Scholar
• Byrne RA, Schulz S, Mehilli J et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety and Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am. Heart J.157(4), 620–624.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, Van Der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J.154(2), 221–231 (2007).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the crest study. J. Am. Coll. Cardiol.46(10), 1827–1832 (2005).
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv.59(3), 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res.115(1–2), 101–108 (2005).
   PubMed Web of Science ®Google Scholar
• Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost.89(5), 783–787 (2003).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol.49(14), 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Hulot JS, Bura A, Villard E et al. Cytochrome p450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood108(7), 2244–2247 (2006).
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation119(2), 237–242 (2009).
   PubMed Web of Science ®Google Scholar
• Von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-choice (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation112(19), 2946–2950 (2005).
   PubMed Web of Science ®Google Scholar
• Bonello L, Lemesle G, De Labriolle A et al. Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention. Am. J. Cardiol.102(10), 1318–1322 (2008).
   Google Scholar
• Angiolillo DJ, Bernardo E, Palazuelos J et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb. Haemost.99(1), 161–168 (2008).
   PubMed Web of Science ®Google Scholar
• Lemesle G, Delhaye C, Sudre A et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am. Heart J.157(2), 375–382 (2009).
   PubMed Web of Science ®Google Scholar
• Mehta SR. A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: results of the current OASIS 7 trial. Presented at: European Society of Cardiology. Barcelona, Spain, 30 August 2009.
   Google Scholar
• Cuisset T, Frere C, Quilici J et al. Glycoprotein iib/iiia inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc. Interv.1(6), 649–653 (2008).
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, De Cesare N et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation119(25), 3215–3222 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P, Goto S et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the Optimus-2 study. Eur. Heart J.29(18), 2202–2211 (2008).
   PubMed Web of Science ®Google Scholar
• Campo G, Valgimigli M, Gemmati D et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J. Am. Coll. Cardiol.50(12), 1132–1137 (2007).
   PubMed Web of Science ®Google Scholar
• Riddell JW, Chiche L, Plaud B, Hamon M. Coronary stents and noncardiac surgery. Circulation116(16), e378–e382 (2007).
   Google Scholar
• Anwaruddin S, Askari AT, Saudye H et al. Characterization of post-operative risk associated with prior drug-eluting stent use. JACC Cardiovasc. Interv.2(6), 542–549 (2009).
   Google Scholar
• Van Werkum JW, Heestermans AA, De Korte FI et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation119(6), 828–834 (2009).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Emanuelsson H, Van Der Giessen W et al. Heparin-coated palmaz-schatz stents in human coronary arteries: early outcome of the BENESTENT II pilot study. Circulation93(3), 412–422 (1996).
   PubMed Web of Science ®Google Scholar
• Serruys P. A progress report from BENESTENT II: heparin coating, restenosis and cost–effectiveness. J. Invasive Cardiol.8(Suppl. E), 22E–24E (1996).
   Google Scholar
• Serruys PW, Van Hout B, Bonnier H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet352(9129), 673–681 (1998).
   PubMed Web of Science ®Google Scholar
• Stone GW, Brodie BR, Griffin JJ et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation99(12), 1548–1554 (1999).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Broderick TM, Roth EM et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am. J. Cardiol.84(4), 391–395 (1999).
   PubMed Web of Science ®Google Scholar
• D’urbano M, Barlocco F, Poli A et al. Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy. J. Cardiovasc. Med. (Hagerstown)9(7), 737–741 (2008).
   PubMed Web of Science ®Google Scholar
• Parodi G, Memisha G, Bellandi B et al. Effectiveness of primary percutaneous coronary interventions for stent thrombosis. Am. J. Cardiol.103(7), 913–916 (2009).
   Google Scholar
• Tu JV, Bowen J, Chiu M et al. Effectiveness and safety of drug-eluting stents in ontario. N. Engl. J. Med.357(14), 1393–1402 (2007).
   PubMed Web of Science ®Google Scholar
• Windecker S, Juni P. Safety of drug-eluting stents. Nat. Clin. Pract. Cardiovasc. Med.5(6), 316–328 (2008).
   Google Scholar
• Grube E, Dawkins K, Guagliumi G et al. Taxus VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention4(5), 572–577 (2009).
   PubMed Web of Science ®Google Scholar
• Lemos PA, Serruys PW, Van Domburg RT et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ‘real world’: the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (research) registry. Circulation109(2), 190–195 (2004).
   PubMed Web of Science ®Google Scholar
• Daemen J, Simoons ML, Wijns W et al. ESC forum on drug eluting stents European Heart House, Nice, 27–28 September 2007. Eur. Heart J.30(2), 152–161 (2009).
   Google Scholar
• Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med.356(15), 1503–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet372(9644), 1163–1173 (2008).
   PubMed Web of Science ®Google Scholar
• Chevalier B, Silber S, Park S-J et al. Randomized comparison of the nobori biolimus A9-eluting coronary stent with the taxus liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial – Phase 2. Circ. Cardiovasc. Intervent.2(3), 188–195 (2009).
   PubMed Web of Science ®Google Scholar
• Van Der Giessen WJ, Sorop O, Serruys PW, Peters-Krabbendam I, Van Beusekom HMM. Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. J. Am. Coll. Cardiol. Interv.2(4), 284–290 (2009).
   Google Scholar
• Costa JR Jr, Abizaid A, Costa R et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the Vestasync I trial. J. Am. Coll. Cardiol. Intv2(5), 422–427 (2009).
   Google Scholar
• Silber S, De Winter R, Grisold M et al. Abstract 6000: clinical outcome for the endothelial progenitor cells capturing genous stent: first results of the 1-year follow-up in 5000 patients. Circulation118(18_MeetingAbstracts), S_1043-a- (2008).
   Google Scholar
• Tamburino C, La Manna A, Di Salvo ME et al. First-in-man 1-year clinical outcomes of the catania coronary stent system with nanothin polyzene-f in de novo native coronary artery lesions: the ATLANTA (Assessment of the Latest Non-Thrombogenic Angioplasty Stent) trial. JACC Cardiovasc. Interv.2(3), 197–204 (2009).
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Annala A-P, Ylitalo A, Vahlberg T, Airaksinen KEJ. Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. Int. J. Cardiol. (2009) (Epub ahead of print).
   Google Scholar
• Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet369(9576), 1869–1875 (2007).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (absorb): a prospective open-label trial. Lancet371(9616), 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (absorb): 2-year outcomes and results from multiple imaging methods. Lancet373(9667), 897–910 (2009).
   PubMed Web of Science ®Google Scholar
• Van De Werf F. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur. Heart J.30(14), 1695–1702 (2009).
   Google Scholar
• Wiviott SD, Braunwald E, Mccabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott Sd, Braunwald E, Mccabe CH et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet371(9621), 1353–1363 (2008).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Schomig A. Ticagrelor – is there need for a new player in the antiplatelet-therapy field? N. Engl. J. Med.361(11), 1108–1111 (2009).
   PubMed Web of Science ®Google Scholar
• Schatz RA, Baim DS, Leon M et al. Clinical experience with the palmaz-schatz coronary stent. Initial results of a multicenter study. Circulation83(1), 148–161 (1991).
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N. Engl. J. Med.331(8), 496–501 (1994).
   PubMed Web of Science ®Google Scholar